Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1204
Shown on this page
12
Current sort
Recently updated
Campus scope
Columbia University Irving Medical Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Columbia University Irving Medical Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 337–348 of 1,204 matching trials with a site at Columbia University Irving Medical Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional Results available

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT03614260
Site status not listed — check the official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Active, not recruiting Not applicable Interventional

Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals

NCT04058561
Site status not listed — check the official record
Conditions
Early-Onset Scoliosis Deformity of Spine
Interventions
MAGEC® Spinal Bracing And Distraction System
Device
Lead sponsor
Pediatric Spine Foundation
Other
Eligibility
5 Years to 9 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Recruiting Not applicable Interventional

A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer

NCT07223463
Status at this site: Not yet recruiting
Conditions
Cancer, Medication Adherence
Interventions
Tailored Program, Feedback Program (Uniform Standard of Care)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Kansas City, Kansas • New York, New York • Cincinnati, Ohio + 1 more
Active, not recruiting Phase 3 Interventional

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

NCT04042025
Site status not listed — check the official record
Conditions
Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
Interventions
Onasemnogene Abeparvovec-xioi
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
18
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Recruiting Not applicable Interventional

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960
Status at this site: Recruiting
Conditions
Aortic Stenosis, Severe
Interventions
SAPIEN X4 THV, SAPIEN X4S
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
58
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
Recruiting No phase listed Observational

Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children

NCT06529575
Status at this site: Not yet recruiting
Conditions
Pediatric ALL, Cardiac Defect
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
4 Weeks to 18 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Houston, Texas
Not yet recruiting Not applicable Interventional

Brain Function and Cognitive Control Training in Children With Obsessive-Compulsive Symptoms

NCT07839013
Site status not listed — check the official record
Conditions
Obsessive-Compulsive Symptoms, Cognitive Control
Interventions
Cognitive Control Training
Device
Lead sponsor
Columbia University
Other
Eligibility
8 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
Status at this site: Active, not recruiting
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

NCT04729959
Site status not listed — check the official record
Conditions
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions
Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab
Biological · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
110
States / cities
Anaheim, California • Bellflower, California • Los Angeles, California + 89 more
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Recruiting No phase listed Observational Accepts healthy volunteers

American Lung Association (ALA) Lung Health Cohort

NCT04543461
Status at this site: Not yet recruiting
Conditions
Lung Diseases
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 35 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Active, not recruiting Phase 3 Interventional

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255
Site status not listed — check the official record
Conditions
Lymphoma, Mantle-Cell
Interventions
Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more

About this Columbia University Irving Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.